Organoids in petri dish
© Gouti Lab /Diecke TP | Felix Petermann, Max Delbrück Center

Overview of Our Portfolio

Max Delbrück Center offers a diverse and translation-focused technology portfolio spanning therapeutics, diagnostics, enabling tools, and advanced discovery platforms. Our assets are IP-protected, scientifically tested, and designed for supporting industry partners from early discovery through clinical development. 

Therapeutics

  • First-in-class therapeutic approaches, including small molecules and rational combination strategies.
  • Programs addressing high-unmet-need areas such as oncology, neurology, inflammation, fibrosis, and rare diseases.
  • Opportunities for spin-out formation, licensing, and co-development. 

Diagnostics

  • Functional, mechanism-based diagnostic technologies enabling patient stratification and therapy guidance.
  • Multi-omics and single-molecule approaches delivering actionable biomarkers across immunology, oncology, and chronic diseases.
  • Scalable approaches suitable for lab diagnostics and potential companion diagnostic development. 

Tool Solutions

  • Enabling technologies for genome engineering, synthetic biology, and protein production.
  • Single-cell and spatial biology methods to accelerate biopharmaceutical development. 
  • Broad applicability across biotech, pharma, and advanced research workflows. 

Drug & Biomarker Discovery Platforms

  • Human-relevant model systems and phenotypic screening platforms capturing disease complexity and treatment response.
  • AI-enabled, high-content discovery tools supporting target identification, biomarker development, and lead optimization.
  • Designed for scalability, reproducibility, and predictive power in drug development pipelines. 

Download the overview here (PDF)

We also offer scientific services, please browse our Technology Platforms page.

Related news & events

scientific image

Left: Muscle fibers expressing dysferlin (purple) made from gene-edited muscle stem cells transplanted into a mouse that lacks dysferlin. Right: Muscle fibers from the recipient mouse that are diseased and lack dysferlin.

© Andreas Marg, AG Spuler, ECRC
Press Release No. 1

Developing a CRISPR therapy for muscular dystrophy

Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular dystrophy with the help of gene-editing. Preclinical research led by the Spuler Lab published in ​“Nature Communications” now paves the way for first-in-human clinical trials. 
woman
Science

From research to application

The Max Delbrück Center proudly welcomes Dr. Nevine Shalaby as the new Head of the Innovation and Entrepreneurship Department. With a rich background in genetics and industry, she aims to drive research impact, foster spin-offs, and strengthen industry partnerships, aligned with the Strategy 2030. 
Wissenschaftliches Bild
© David Ausserhofer, Max Delbrück Center
Press Release No. 22

Sharpening the gene scissors together

The Max Delbrück Center, Berlin, and the biotech company AlgenScribe from Nice have agreed to cooperate to further develop their gene-editing tools. The aim is to utilize synergies, accelerate research, and ultimately develop cell therapies for genetically determined diseases. 
Bild aus dem Labor
© Glycotope GmbH
Science

Research collaboration to improve immunotherapies

The Berlin biotech Glycotope and the Max Delbrück Center have signed an agreement to explore the potential of combining Glycotope’s tumor-specific antibodies with CAR technology developed by the Max Delbrück Center. Their common goal: advancing immunotherapies against solid tumors.